Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide

IntroductionTreatment and management of obesity is clinically challenging. The inclusion of GLP-1 receptor agonists (GLP1RA) in the medical management of obesity has proven to be efficacious. However, mechanisms underlying the molecular changes arising from GLP1RA treatment in patients with obesity...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Afshan Masood, Hicham Benabdelkamel, Salini Scaria Joy, Abdulaziz Alhossan, Bashayr Alsuwayni, Ghalia Abdeen, Madhawi Aldhwayan, Nora A. Alfadda, Alexander Dimitri Miras, Assim A. Alfadda
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2024-09-01
Серія:	Frontiers in Molecular Biosciences
Предмети:	obesity liraglutide GLP1 receptor agonist proteomics label-free quantification multimerin-2
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fmolb.2024.1458675/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide

Схожі ресурси